Tealwood Asset Management Inc. Sells 33,458 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Tealwood Asset Management Inc. cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 63.4% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 19,355 shares of the biopharmaceutical company's stock after selling 33,458 shares during the quarter. Tealwood Asset Management Inc.'s holdings in Halozyme Therapeutics were worth $1,235,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its position in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the period. Louisiana State Employees Retirement System boosted its holdings in Halozyme Therapeutics by 0.6% during the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock worth $1,688,000 after buying an additional 200 shares during the last quarter. Parallel Advisors LLC boosted its holdings in Halozyme Therapeutics by 12.5% during the first quarter. Parallel Advisors LLC now owns 1,875 shares of the biopharmaceutical company's stock worth $120,000 after buying an additional 208 shares during the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 2.0% during the 4th quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock valued at $532,000 after purchasing an additional 221 shares in the last quarter. Finally, Portside Wealth Group LLC lifted its holdings in shares of Halozyme Therapeutics by 2.4% during the 1st quarter. Portside Wealth Group LLC now owns 9,317 shares of the biopharmaceutical company's stock valued at $595,000 after purchasing an additional 222 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Benchmark cut Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. HC Wainwright restated a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Leerink Partners lowered Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target on the stock. in a research report on Tuesday, May 13th. Finally, Morgan Stanley lowered Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $73.00 to $62.00 in a research report on Wednesday, May 14th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of "Hold" and an average price target of $61.90.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $54.25 on Friday. The stock's 50-day simple moving average is $57.96 and its 200 day simple moving average is $55.84. The firm has a market capitalization of $6.68 billion, a PE ratio of 15.82, a price-to-earnings-growth ratio of 0.42 and a beta of 1.19. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same period last year, the firm posted $0.79 earnings per share. The business's revenue for the quarter was up 35.2% on a year-over-year basis. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the completion of the sale, the director now directly owns 33,108 shares in the company, valued at approximately $2,120,567.40. The trade was a 1.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.